Skip to main content
. 2021 Sep 13;15:17534666211042529. doi: 10.1177/17534666211042529

Figure 4.

Figure 4.

Mortality in IPF patients subdivided according to the carriage of DSP rs2076295*G allele treated with (a) nintedanib or pirfenidone or (b) without antifibrotic treatment and comparison between nintedanib or pirfenidone treatments versus without antifibrotic treatment for (c) *T allele carriers and (d) GG genotypes.